Coens, C., Suciu, S., Chiarion-Sileni, V., Grob, J., Dummer, R., Wolchok, J. D., . . . Eggermont, A. (2017). Phase III trial (EORTC 18071 / CA184-029) of post-operative adjuvant ipilimumab compared to placebo in patients with resected stage III cutaneous melanoma: Health Related Quality of Life (HRQoL) results. Lancet Oncol.
Stile di citazione ChicagoCoens, Corneel, et al. "Phase III Trial (EORTC 18071 / CA184-029) of Post-operative Adjuvant Ipilimumab Compared to Placebo in Patients With Resected Stage III Cutaneous Melanoma: Health Related Quality of Life (HRQoL) Results." Lancet Oncol 2017.
Citazione MLACoens, Corneel, et al. "Phase III Trial (EORTC 18071 / CA184-029) of Post-operative Adjuvant Ipilimumab Compared to Placebo in Patients With Resected Stage III Cutaneous Melanoma: Health Related Quality of Life (HRQoL) Results." Lancet Oncol 2017.